Memorial Sloan Kettering Cancer Center, New York, New York, USA.
University of California Berkeley, Berkeley, California, USA.
Cancer. 2024 Nov 15;130(22):3913-3925. doi: 10.1002/cncr.35478. Epub 2024 Jul 27.
Older head and neck cancer (HNC) survivors have concerning rates of potentially unsafe opioid prescribing. Identifying the specialties of opioid prescribers for HNC survivors is critical for targeting the settings for opioid safety interventions. This study hypothesized that oncology and surgery providers are primarily responsible for opioid prescriptions in the year after treatment but that primary care providers (PCPs) are increasingly involved in prescribing over time.
Using linked Surveillance, Epidemiology, and End Results-Medicare data, a retrospective analysis was conducted of adults aged >65 years diagnosed between 2014 and 2017 with stage I-III HNC and who had ≥6 months of treatment-free follow-up through 2019. Starting at treatment completion, opioid fills were assigned to a prescriber specialty: oncology, surgery, primary care, pain management, or other. Prescriber patterns were summarized for each year of follow-up. Multinomial logistic regression models captured the likelihood of opioids being prescribed by each specialty.
Among 5135 HNC survivors, 2547 (50%) had ≥1 opioid fill (median, 2.1-year follow-up). PCPs prescribed 47% of all fills (42%-55% each year). PCPs prescribed opioids to 45% of survivors with ≥1 opioid fill, which was a greater share than other specialties. PCPs prescribed longer supplies of opioids (median, 20 days/fill; median, 30 days/year) than oncologists or surgeons. The likelihood of an opioid being prescribed by an oncology provider was four times lower than that of it being prescribed by a PCP.
PCP involvement in opioid prescribing remains high throughout HNC survivorship. Interventions to improve the safety of opioid prescribing should target primary care, as is typical for opioid reduction efforts in the noncancer population.
老年头颈部癌症(HNC)幸存者的阿片类药物处方存在潜在安全问题。确定 HNC 幸存者的阿片类药物处方开具者的专业范围对于确定阿片类药物安全干预措施的目标环境至关重要。本研究假设,肿瘤学和外科医生主要负责治疗后一年的阿片类药物处方,但随着时间的推移,初级保健提供者(PCP)越来越多地参与处方。
使用链接的监测、流行病学和最终结果-医疗保险数据,对 2014 年至 2017 年间诊断为 I-III 期 HNC 且在 2019 年之前有≥6 个月无治疗随访的年龄>65 岁的成年人进行回顾性分析。从治疗结束开始,将阿片类药物的处方分配给专科医生:肿瘤学、外科、初级保健、疼痛管理或其他。总结了每个随访年的处方模式。多变量逻辑回归模型捕捉了每个专科医生开具阿片类药物的可能性。
在 5135 名 HNC 幸存者中,有 2547 名(50%)至少有 1 次阿片类药物处方(中位数,2.1 年随访)。PCP 开具了所有处方的 47%(每年 42%-55%)。PCP 为≥1 次阿片类药物处方的 45%的幸存者开具了阿片类药物,这一比例高于其他专科医生。PCP 开具的阿片类药物供应时间更长(中位数,20 天/次;中位数,每年 30 天)。与肿瘤学家或外科医生相比,PCP 开具阿片类药物的可能性低四倍。
在 HNC 幸存者中,PCP 参与阿片类药物处方仍然很高。改善阿片类药物处方安全的干预措施应针对初级保健,这与非癌症人群中减少阿片类药物的努力是一致的。